Liquidia (NASDAQ:LQDA) Stock Price Expected to Rise, Raymond James Analyst Says

Liquidia (NASDAQ:LQDA) had its price target upped by investment analysts at Raymond James from $27.00 to $29.00 in a report released on Friday,Benzinga reports. The brokerage presently has a “strong-buy” rating on the stock. Raymond James’ target price points to a potential upside of 89.30% from the stock’s previous close.

A number of other equities analysts have also recently weighed in on LQDA. Needham & Company LLC reissued a “buy” rating and issued a $25.00 price target on shares of Liquidia in a research note on Thursday, April 10th. Scotiabank restated an “outperform” rating on shares of Liquidia in a report on Monday, May 5th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Liquidia in a research note on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Liquidia has an average rating of “Buy” and an average price target of $27.13.

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $15.32 on Friday. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of -9.40 and a beta of 0.24. Liquidia has a 12 month low of $8.26 and a 12 month high of $16.81. The stock’s 50 day moving average price is $14.25 and its 200 day moving average price is $13.16.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. On average, sell-side analysts expect that Liquidia will post -1.51 EPS for the current year.

Insider Buying and Selling

In other Liquidia news, CFO Michael Kaseta sold 8,283 shares of the stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $112,400.31. Following the transaction, the chief financial officer now directly owns 396,315 shares of the company’s stock, valued at $5,377,994.55. This represents a 2.05 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jason Adair sold 1,856 shares of the business’s stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $25,185.92. Following the completion of the sale, the insider now directly owns 184,304 shares of the company’s stock, valued at $2,501,005.28. This represents a 1.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,138 shares of company stock worth $450,233. Corporate insiders own 26.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in LQDA. CenterBook Partners LP acquired a new position in Liquidia during the first quarter valued at approximately $1,786,000. Hurley Capital LLC acquired a new position in Liquidia in the 1st quarter valued at $32,000. Cetera Investment Advisers raised its holdings in Liquidia by 34.4% in the 1st quarter. Cetera Investment Advisers now owns 41,999 shares of the company’s stock worth $619,000 after acquiring an additional 10,756 shares during the period. Bleakley Financial Group LLC raised its holdings in Liquidia by 6.4% in the 1st quarter. Bleakley Financial Group LLC now owns 25,308 shares of the company’s stock worth $373,000 after acquiring an additional 1,523 shares during the period. Finally, Significant Wealth Partners LLC lifted its position in Liquidia by 14.1% during the 1st quarter. Significant Wealth Partners LLC now owns 14,396 shares of the company’s stock worth $212,000 after acquiring an additional 1,780 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).